92992-91-1

Upstream product

• 109-04-6 2-bromo-pyridine 
• 110-60-1 1,4-diaminobutane 
• 109-09-1 2-chloropyridine 
• 5029-67-4 2-iodopyridine 

Downstream Products

• 93235-06-4 2-[N-(4-aminobutyl)-N-benzylamino]pyridine 
• 1401015-08-4 5-(1H-indol-3-yl)methyl-1-(4-bromobenzyl)-3-(4-(pyridin-2-ylamino)butyl)-2-thioxoimidazolidin-4-one 
• 1401015-09-5 1-(3,4-dichlorobenzyl)-5-(1H-indol-3-yl)methyl-3-((4-pyridin-2-ylamino)butyl)-2-thioxoimidazolidin-4-one 
• 1555940-37-8 2-cyano-1-[2-(phenylthio)ethyl]-3-[4-(pyridin-2-ylamino)butyl]guanidine 

Relevant academic research and scientific papers

Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands

Imbutamine (4-(1H-imidazol-4-yl)butanamine) is a potent histamine H 3 (H3R) and H4 receptor (H4R) agonist (EC50 values: 3 and 66 nM, respectively). Aiming at improved selectivity for the H4R, the imidazole ring in imbutamine was methyl-substituted or replaced by various differently substituted heterocycles (1,2,3-triazoles, 1,2,4-triazoles, pyridines, pyrimidines) as potential bioisosteres. Investigations in [35S]GTPγS binding assays using membranes of Sf9 insect cells expressing the respective human histamine receptor subtype revealed only very weak activity of most of the synthesized hetarylalkylamines at both receptors. By contrast, the introduction of substituents at the 4-imidazolyl ring was most effective regarding H 4R selectivity. This holds for methyl substitution in position 2 and, especially, in position 5. 5-Methylimbutamine (H4R: EC50 = 59 nM, α = 0.8) was equipotent with imbutamine at the hH4R, but revealed about 16-fold selectivity for the hH4R compared to the hH3R (EC50 980 nM, α = 0.36), whereas imbutamine preferred the hH3R. The functional activities were in agreement with radioligand binding data. The results support the hypothesis that, by analogy with histamine, methyl substitution in histamine homologs offers a way to shift the selectivity in favor of the H4R. According to a bioisosteric approach, the imidazole ring in the dual histamine H3/H4 receptor agonist imbutamine (n = 4) was replaced by various five- and six-membered N-heterocycles. Whereas these structural modifications resulted in a reduction or loss of activity at both receptors, 5-methyl substitution at the imidazol-4-yl ring in imbutamine changed the receptor subtype selectivity in favor of the H4R.

Structure-activity-relationship studies around the 2-amino group and pyridine core of antimalarial 3,5-diarylaminopyridines lead to a novel series of pyrazine analogues with oral in vivo activity

Replacement of the pyridine core of antimalarial 3,5-diaryl-2- aminopyridines led to the identification of a novel series of pyrazine analogues with potent oral antimalarial activity. However, other changes to the pyridine core and replacement or substitution of the 2-amino group led to loss of antimalarial activity. The 3,5-diaryl-2-aminopyrazine series showed impressive in vitro antiplasmodial activity against the K1 (multidrug resistant) and NF54 (sensitive) strains of Plasmodium falciparum in the nanomolar IC50 range of 6-94 nM while also demonstrating good in vitro metabolic stability in human liver microsomes. In the Plasmodium berghei mouse model, this series generally exhibited good efficacy at low oral doses. One of the frontrunner compounds, 4, displayed potent in vitro antiplasmodial activity with IC 50 values of 8.4 and 10 nM against the K1 and NF54 strains, respectively. When evaluated in P. berghei-infected mice, compound 4 was completely curative at an oral dose of 4 × 10 mg/kg.

Amine modification of digested peptide at C-terminal end during protein digestion by protease

We recently reported that C-terminal polyamine modification occurs when proteins are digested with trypsin in the presence of polyamine [Biochem. Biophys. Res. Commun., 356, 159-162 (2007)]. In the present study, the characteristics of this C-terminal modification in the presence of protease and amine were investigated. When hemoglobin (HB) was digested with trypsin in the presence of N-(2-pyridyl)-1,4-diaminobutane (Py4), formation of the modified peptide was dependent on time and on HB or Py4 concentration. When synthetic peptide was treated with trypsin in the presence of Py4, ca. 0.1% of the peptide was modified with Py4. When HB or cytochrome C was treated with a range of serine proteases in the presence of various amines (Py4, N-(2-pyridyl)-1,3- diaminopropane, tranexamic acid, isonicotinic acid hydrazide and ampicillin), the modified peptide was detected in all cases tested, thus suggesting that amine modification widely accompanies digestion by proteases.

CATIONIC BACTERIOCHLOROPHYLL DERIVATIVES AND USES THEREOF

The invention provides cationic tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one positively charged group and/or at least one basic group that is converted to a positively charged group under physiological conditions, preferably Bchls having an onium group derived from a N-containing aliphatic or heterocyclic radical such as ammonium, guanidinium, imidazolium, pyridinium, and the like or a phosphonium, arsonium, oxonium, sulfonium, selenonium, telluronium, stibonium, or bismuthonium group, or a basic group that is converted to such onium groups under physiological conditions, said groups being bound to one or more of the positions 173, 133 and 32 of the Bchl molecule by ester or amide bond. The Bchls are useful for photodynamic therapy and diagnosis.

Nonpeptide somatostatin agonists with sst4 selectivity: Synthesis and structure-activity relationships of thioureas

Utilizing NNC 26-9100 (11) as a structural lead, a variety of nonpeptide derivatives of somatostatin were synthesized and evaluated for sst2 and sst4 receptor binding affinity. A novel thiourea scaffold was utilized to attach (1) a h

3-PYRIDYLAMINOALKYLENEAMINO-4-AMINO-1,2,5-THIADIAZOLE-1-OXIDES, COMPOSITION CONTAINING THEM, AND USE OF THEM TO BLOCK HISTAMINE H2-RECEPTORS

New 3,4-diamino-1,2,5-thiadiazole oxide derivatives which are histamine H 1-antagonists. A specific compound of this invention is 3-3-(N-propyl-N-2-pyridylamino)-propylamino!-4-(4-pyridylmethyl)amino-1, 2, 5-t hiadiazole-1-oxide.

2-(2-Pyridylaminoalkylamino)-4-pyrimidones

Pyridine derivatives are disclosed which are useful as histamine H1 -antagonists.

2-Pyridylaminoakylamino-4-pyrimidones useful as histamine H1 -antagonists

Pyridine derivatives are disclosed which are useful as histamine H1 -antagonists.

Pyridylaminoalkylaminopyrimidones useful as histamine H1 -antagonists

Pyridine derivatives are disclosed which are useful as histamine H1 -antagonists.